HemaSphere (Jun 2022)
P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA
- A. Bazinet,
- T. Kadia,
- N. Short,
- G. Borthakur,
- S. Wang,
- S. Loghavi,
- J. Jorgensen,
- K. Patel,
- C. DiNardo,
- N. Daver,
- Y. Alvarado,
- F. Haddad,
- S. Pierce,
- M. Andreeff,
- E. Jabbour,
- M. Konopleva,
- H. Kantarjian,
- F. Ravandi
Affiliations
- A. Bazinet
- 1 Leukemia
- T. Kadia
- 1 Leukemia
- N. Short
- 1 Leukemia
- G. Borthakur
- 1 Leukemia
- S. Wang
- 2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America
- S. Loghavi
- 2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America
- J. Jorgensen
- 2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America
- K. Patel
- 2 Hematopathology, University of Texas MD Anderson Cancer Center, Houston, United States of America
- C. DiNardo
- 1 Leukemia
- N. Daver
- 1 Leukemia
- Y. Alvarado
- 1 Leukemia
- F. Haddad
- 1 Leukemia
- S. Pierce
- 1 Leukemia
- M. Andreeff
- 1 Leukemia
- E. Jabbour
- 1 Leukemia
- M. Konopleva
- 1 Leukemia
- H. Kantarjian
- 1 Leukemia
- F. Ravandi
- 1 Leukemia
- DOI
- https://doi.org/10.1097/01.HS9.0000844912.65235.a5
- Journal volume & issue
-
Vol. 6
pp. 405 – 406
Abstract
No abstracts available.